Acarix AB
7AC
Company Profile
Business description
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics.
Contact
Hyllie Boulevard 34, 5TR
c/o Regus Hyllie
Malmo215 32
SWESector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
There are 3 good reasons to buy this US dividend stock today
It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.
stocks
Strategic reset for ASX listed share
The global search for a new CEO is over, ending investor concern about leadership uncertainty.
stocks
ASX listed bank overvalued after shares surge
Investors were pleased with results but our fair value estimate is unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.80 | 5.80 | -0.06% |
| CAC 40 | 8,316.50 | 4.76 | 0.06% |
| DAX 40 | 24,800.91 | 113.97 | -0.46% |
| Dow JONES (US) | 49,497.29 | 45.31 | 0.09% |
| FTSE 100 | 10,473.69 | 27.34 | 0.26% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,806.41 | 135.56 | -0.24% |
| NZX 50 Index | 13,128.14 | 10.23 | 0.08% |
| S&P 500 | 6,840.79 | 8.03 | 0.12% |
| S&P/ASX 200 | 8,937.10 | 8.30 | -0.09% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |